{"title":"177Lu-PSMA治疗转移性前列腺癌的显著反应一例报告。","authors":"Aysenur Sinem Erdogan, Haluk Sayan, Bedri Seven, Berna Okudan","doi":"10.2174/0115734056362468250709045212","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In nuclear medicine, Prostate-specific Membrane Antigen (PSMA) is a potential target for theranostics. Offering superior diagnostic accuracy to conventional imaging in prostate cancer (PCa), Gallium-68 labeled PSMA (<sup>68</sup>Ga-PSMA) positron emission tomography/computed tomography (PET/CT) is considered the new standard of care in PCa management. Tumor cells identified as PSMA-avid on PET/CT imaging can be targeted and eliminated with PSMA-labeled Lutetium-177 (<sup>177</sup>Lu-PSMA) therapy.</p><p><strong>Case presentation: </strong>A sixty-eight years old patient who had metastatic castration-resistant PCa was reported in this study. Prior to receiving <sup>177</sup>Lu-PSMA therapy, the patient's PSA level was 358 ng/ml, and experienced extensive bone discomfort. Following ten cycles of <sup>177</sup>Lu-PSMA therapy, exceptional results were observed.</p><p><strong>Conclusion: </strong><sup>177</sup>Lu-PSMA therapy is likely to result in significantly better outcomes if first- or second-line treatments preserve the patient's bone marrow reserve or if the therapy is administered at earlier stages of the disease.</p>","PeriodicalId":54215,"journal":{"name":"Current Medical Imaging Reviews","volume":" ","pages":"e15734056362468"},"PeriodicalIF":1.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Case Report on the Dramatic Response of <sup>177</sup>Lu-PSMA Therapy for Metastatic Prostate Cancer.\",\"authors\":\"Aysenur Sinem Erdogan, Haluk Sayan, Bedri Seven, Berna Okudan\",\"doi\":\"10.2174/0115734056362468250709045212\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In nuclear medicine, Prostate-specific Membrane Antigen (PSMA) is a potential target for theranostics. Offering superior diagnostic accuracy to conventional imaging in prostate cancer (PCa), Gallium-68 labeled PSMA (<sup>68</sup>Ga-PSMA) positron emission tomography/computed tomography (PET/CT) is considered the new standard of care in PCa management. Tumor cells identified as PSMA-avid on PET/CT imaging can be targeted and eliminated with PSMA-labeled Lutetium-177 (<sup>177</sup>Lu-PSMA) therapy.</p><p><strong>Case presentation: </strong>A sixty-eight years old patient who had metastatic castration-resistant PCa was reported in this study. Prior to receiving <sup>177</sup>Lu-PSMA therapy, the patient's PSA level was 358 ng/ml, and experienced extensive bone discomfort. Following ten cycles of <sup>177</sup>Lu-PSMA therapy, exceptional results were observed.</p><p><strong>Conclusion: </strong><sup>177</sup>Lu-PSMA therapy is likely to result in significantly better outcomes if first- or second-line treatments preserve the patient's bone marrow reserve or if the therapy is administered at earlier stages of the disease.</p>\",\"PeriodicalId\":54215,\"journal\":{\"name\":\"Current Medical Imaging Reviews\",\"volume\":\" \",\"pages\":\"e15734056362468\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Medical Imaging Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115734056362468250709045212\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Imaging Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115734056362468250709045212","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
A Case Report on the Dramatic Response of 177Lu-PSMA Therapy for Metastatic Prostate Cancer.
Introduction: In nuclear medicine, Prostate-specific Membrane Antigen (PSMA) is a potential target for theranostics. Offering superior diagnostic accuracy to conventional imaging in prostate cancer (PCa), Gallium-68 labeled PSMA (68Ga-PSMA) positron emission tomography/computed tomography (PET/CT) is considered the new standard of care in PCa management. Tumor cells identified as PSMA-avid on PET/CT imaging can be targeted and eliminated with PSMA-labeled Lutetium-177 (177Lu-PSMA) therapy.
Case presentation: A sixty-eight years old patient who had metastatic castration-resistant PCa was reported in this study. Prior to receiving 177Lu-PSMA therapy, the patient's PSA level was 358 ng/ml, and experienced extensive bone discomfort. Following ten cycles of 177Lu-PSMA therapy, exceptional results were observed.
Conclusion: 177Lu-PSMA therapy is likely to result in significantly better outcomes if first- or second-line treatments preserve the patient's bone marrow reserve or if the therapy is administered at earlier stages of the disease.
期刊介绍：
Current Medical Imaging Reviews publishes frontier review articles, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances on medical imaging dedicated to clinical research. All relevant areas are covered by the journal, including advances in the diagnosis, instrumentation and therapeutic applications related to all modern medical imaging techniques.
The journal is essential reading for all clinicians and researchers involved in medical imaging and diagnosis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
